Evidence map›Paper›PMID 42707988›Full record

ArticleTheranostics2026

An integrated SOX4-driven transcriptional and metabolic program governs tumor-infiltrating regulatory T cells in ovarian cancer.

Lei Wu, Ziqi Tao, Yuelu Zhang, Yepeng Mao, Lei Zhang, Lina Yan, Rong Li, Lingfei Zhou, Zhijie Liu, Wenwen Shang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lei WuDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Ziqi TaoDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Yuelu ZhangDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Yepeng MaoDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Lei ZhangDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Lina YanDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Rong LiDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Lingfei ZhouDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Zhijie LiuDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Wenwen ShangDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Shuna LiuDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Jianfang LouDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Xi HuangDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Ting WangDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.
Fang WangDepartment of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Regulatory T cells (Tregs) suppress antitumor immunity in ovarian cancer (OC) and are promising targets for immunotherapy. However, the heterogeneity and regulatory mechanisms of tumor-infiltrating Tregs (TI-Tregs) remain poorly defined. Here, we aim to delineate TI-Treg programs to identify potential therapeutic targets. Methods: CD4⁺CD25⁺CD127⁻ Tregs from OC, adjacent tissues, and peripheral blood were profiled by single-cell RNA sequencing and spatial transcriptomics, with regulatory networks inferred using SCENIC. Functional and mechanistic studies of SOX4 were performed using hypoxic/tumor-conditioned models, CRISPR-Cas9 perturbation, ectopic overexpression, Cut&Tag profiling, and oxidative phosphorylation (OXPHOS) inhibition. Results: We identified nine transcriptionally distinct Treg subsets, revealing a highly activated and immunosuppressive state among TI-Tregs. These TI-Tregs exhibited strong co-expression of Conclusions: SOX4 is a central regulator of TI-Treg suppressive function and metabolic fitness, representing a promising therapeutic target for OC.

Indexed as

Lymphocytes, Tumor-InfiltratingOvarian NeoplasmsSOXC Transcription FactorsT-Lymphocytes, RegulatoryAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceOxidative PhosphorylationTumor MicroenvironmentSOX4 protein, humanSOXC Transcription Factorsovarian cancerregulatory T cellsSOX4 transcription factortumor microenvironment

Identifiers

PMID42707988
PMCPMC13549143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.